Tsai Henry K, Mauch Peter M
Department of Radiation Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115.
Semin Radiat Oncol. 2007 Jul;17(3):184-9. doi: 10.1016/j.semradonc.2007.02.004.
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), a distinct subtype of Hodgkin lymphoma, is a rare disease with a generally favorable prognosis. The hallmark of NLPHL is the presence of the lymphocytic and histiocytic cell, which, in contrast to the classic Reed-Sternberg cell, is CD20+, CD15-, and CD30-. NLPHL tends to have an indolent natural history, a long time to disease progression, a delayed time to relapse, and a high likelihood of presenting as early-stage disease. The evidence to guide the management of patients with NLPHL is limited by the rarity of this disease, but the available data support the use of involved-field radiation therapy alone for localized disease. Treatment-related late effects contribute significantly to the causes of death in patients treated for NLPHL.
结节性淋巴细胞为主型霍奇金淋巴瘤（NLPHL）是霍奇金淋巴瘤的一种独特亚型，是一种罕见疾病，总体预后较好。NLPHL的标志是存在淋巴细胞和组织细胞，与经典的里德-斯腾伯格细胞不同，该细胞CD20阳性、CD15阴性、CD30阴性。NLPHL往往具有惰性自然病程、疾病进展时间长、复发时间延迟以及早期疾病表现的可能性高。由于这种疾病罕见，指导NLPHL患者管理的证据有限，但现有数据支持对局限性疾病单独使用受累野放射治疗。治疗相关的晚期效应是NLPHL治疗患者死亡原因的重要因素。
